Aran R&D 2025: Defense Is Lifting Revenue, But Earnings Quality Still Isn’t There

Getting To Know The Company

Despite the name, Aran R&D is no longer an R&D lab story. In 2025 it is a small industrial platform with three very different engines: design, development, and manufacturing services, increasingly tied to defense demand; equipment, raw-material, and recycling distribution; and a medical monetization layer through Upstream. On April 6, 2026, market cap stood at about NIS 174.8 million, daily trading turnover was only NIS 15,250, and the group ended the year with 249 employees and roughly NIS 1.06 million of revenue per employee. That context matters because this is a small, illiquid company, so changes in earnings quality matter more than a quick headline reader might think.

What is working now is demand. During 2025 the company received defense-market manufacturing orders totaling NIS 49 million, year-end backlog in design, development, and manufacturing stood at NIS 41.9 million, and a second leg of about NIS 25 million of backlog was already sitting in recycling and waste separation. Cash also looks stronger, NIS 53.8 million versus NIS 20.3 million a year earlier, and the company stresses that it does not carry bank debt for ordinary ongoing operations, only financing tied mainly to customer loans for machine purchases.

But the fast reading misses the heart of the story. At first glance, 2025 looks like a breakout year: revenue of NIS 263.4 million, up 20.8%, operating profit of NIS 32.0 million, and net profit of NIS 25.3 million. In practice, more than two-thirds of pretax profit, NIS 22.1 million out of NIS 32.7 million, came from the investment and startup segment. By contrast, design, development, and manufacturing, the segment that is supposed to carry the defense story, produced NIS 110.2 million of revenue but only NIS 0.4 million of pretax profit. That is the central gap of the year.

That is also the bottleneck for 2026. The company has already shown that it can win orders, build backlog, and maintain broad design and manufacturing capabilities. It has not yet shown that this layer can generate enough clean earnings without help from a medical milestone, working-capital support, or value realization. That is why 2026 currently reads as a proof year, not a breakout year.

Economic Map

Another 14 employees sit in group management and administration.

Events And Triggers

The key read here is that 2025 already brought Aran to a bigger activity base, but not yet to the same clarity in earnings. The important triggers are real. Most of them still sit between the order stage and the proof stage.

Defense Orders Are Here, Margin Still Is Not

First trigger: during 2025 the company received defense-market production orders totaling NIS 49 million. That annual tally includes the December 2025 immediate report on NIS 21.4 million of orders, of which NIS 18.45 million were binding and another NIS 2.95 million was cancellable. One of the binding orders includes a product developed by the company that was selected by the customer as a unique solution in unmanned aerial systems. Deliveries for that layer are expected to stretch over up to 15 months starting in March 2026.

Second trigger: after year-end, another layer arrived, NIS 8.5 million of Ministry of Defense orders, all for delivery during 2026. That is no longer a hint of demand. It is an actual continuation of order flow. What matters is that the segment’s profitability still does not show the kind of clean operating earnings one might expect from that backlog.

That gap looks even sharper once capacity is brought into the picture. The company estimates that, as of the report date, it was still running at below 50% of potential production capacity. That is both an opportunity and a warning. An opportunity because real density could unlock operating leverage. A warning because even after the order wave, the industrial base is still not fully utilizing the infrastructure already in place.

Recycling And Waste Add A Second Leg

Since entering this activity at the end of 2022 and through year-end 2025, cumulative sales to recycling and waste separation reached about NIS 18 million. By the report date, backlog in this leg stood at about NIS 25 million, mostly for 2026, including a EUR 5.2 million municipal waste-sorting project in central Israel. The group is not building a side story here. It is building a real second leg, with the ability to offer design, equipment, and implementation in one package.

That matters because this leg can offset part of the cyclicality of the plastics-machinery market. But it is still too early to get carried away. A meaningful part of the backlog sits on milestone timing and on one large project, so the challenge is not only to win work but to execute it on schedule, keep margin intact, and turn it into something more repeatable.

Upstream Delivered The Earnings Headline

During 2025 Upstream achieved the milestone that entitled it to an immediate EUR 5 million payment from Bentley. Around that milestone, the group recognized a NIS 16 million pretax gain from the sale of rights and know-how. In parallel, the Bentley agreement was extended so Upstream will continue to manufacture and supply the product through September 30, 2026. At the narrative level, this looks strong, and the company explicitly frames it as its fifth exit.

But this is exactly where analytical discipline matters. The cash is real, but it does not prove the industrial core. It proves that the company can originate, develop, and monetize medical value. That is an achievement. It simply sits in a different layer from the earnings the market should be testing in defense and industrial operations.

Control Changed, And Capital Allocation Turned More Aggressive

During 2025 Abraham Zakai sold his holdings, and on August 28, 2025 a new investor group began to be treated as the controlling group, holding 46.07% of the issued share capital. Aharon Cohen became chairman. At the same time, the company repurchased shares from Atrion for NIS 5.38 million and distributed dividends totaling NIS 23.2 million through the report date, including NIS 9.045 million declared in December 2025 and paid in January 2026.

There is a double message here. On one side, new control and large capital returns signal confidence in the asset base. On the other side, when 2025 profit still leaned heavily on Upstream and the defense-facing operating segment has not yet shown enough clean profit, that level of capital return raises the bar for what 2026 now has to prove.

Efficiency, Profitability, And Competition

Aran’s profitability story in 2025 splits in two. The business really did grow. But the growth is not sitting where the fast reader assumes it is sitting. That is why the numbers have to be read engine by engine, not only through the net-profit headline.

Design, Development, And Manufacturing Grew, But Profit Stayed Thin

Revenue in this segment rose to NIS 110.2 million from NIS 99.9 million in 2024 and NIS 91.2 million in 2023. That is real improvement. The problem is that the bottom line of the segment did not move with it. Gross margin fell to 9.7% from 10.7%, and the company explicitly ties that decline mainly to software consulting activity. At the pretax line, the segment reached only NIS 0.4 million.

That is a very low number relative to the order momentum and to the defense framing of the year. It does not mean the activity is weak. It means the activity is not yet dense enough, and that the current mix between production, development, and software consulting still does not converge into a clear, clean margin. Put differently, the company has already proved that demand is there. It has not yet proved that the demand can be distilled into profit.

That said, the segment still has clear structural strengths. The company has more than 40 years of experience, holds in-house design, electronics, software, machining, 3D printing, and manufacturing capabilities, and is an approved supplier to the Ministry of Defense. It also holds the quality certifications that support work in defense and medical projects. That is a real moat. It simply should not be mistaken for clean earnings on its own.

Customer concentration makes the point sharper. Four defense customers account for about 62% of segment revenue. On the one hand, that shows the company is embedded more deeply into the defense system. On the other hand, it is concentration the market cannot ignore, especially if state-budget approval or procurement timing move around.

Equipment, Raw Materials, And Recycling Grew, But On Leaner Economics

This segment generated NIS 138.9 million of revenue in 2025, versus NIS 111.5 million in 2024. That is growth of almost 25%, driven by a mix of raw materials, machines, spare parts, and service. But gross margin fell to 19.0% from 23.7%. The interesting reason does not sit in weak demand. It sits in deal structure: following a request from a key raw-material supplier, more of the business shifted from agency-style economics to distribution-style economics.

That is a classic example of revenue growth that is not automatically equal to quality growth. When a business moves from agency to distribution, it books more revenue, but it also carries more inventory, more working capital, and less margin. So the growth in this segment is real, but it is not free.

There are still clear structural advantages here as well. Aran is the exclusive representative of Engel in injection machines and robots, and of ExxonMobil in raw materials. During 2025 it also signed the agreement to distribute ExxonMobil PP products in Israel, with sales expected to start during 2026. The company has service, spare parts, logistics, and customer-financing capabilities, and this segment is not constrained by production capacity. It can keep growing. The market simply needs to see that margin can stabilize with it.

2025 Profit Sits In A Different Layer

This is where the difference between revenue and earnings quality becomes obvious. The investment and startup segment generated only NIS 14.3 million of revenue, but NIS 22.1 million of pretax profit. That is more than the entire pretax contribution of equipment and raw materials, and more than 50 times the pretax profit of design and manufacturing. So 2025 was not only a year of industrial growth. It was also a year of realization.

That does not mean the profit should be discounted away. It means it needs to be framed correctly. Anyone reading 2025 as the start of a period in which Aran has already become a very profitable defense-industrial company is moving too fast. Anyone reading it as a year in which group earnings jumped because of a combination of industrial growth, a commercial-mix shift, and a medical monetization event is reading it more accurately.

Cash Flow, Debt, And Capital Structure

This is where the framing needs to be explicit. For Aran, the relevant lens is all-in cash flexibility, how much cash is really left after actual uses of cash, not only theoretical operating cash generation. The reason is simple: in 2025 the company also distributed substantial capital, repurchased shares, and benefited from a relatively unusual inflow through Upstream.

The Cash Balance Rose, But Not Only Because Of Recurring Operations

Operating cash flow stood at NIS 58.2 million, versus NIS 36.5 million in 2024. Investing cash flow was positive at NIS 13.6 million, and financing cash flow was negative at NIS 38.2 million. Year-end cash rose to NIS 53.8 million.

At first glance, that looks excellent. On second glance, it needs to be decomposed. The directors' report ties the improvement in operating cash flow to better credit terms with a major supplier in the equipment and raw-materials segment, and to customer advances in the same segment. Positive investing cash flow rested mainly on the roughly NIS 14.5 million after-tax receipt tied to the Upstream milestone. So even the larger year-end cash balance is partly built on layers that do not belong to the fully recurring industrial core.

That is not a technical complaint. It is the exact difference between a company that has already built a clean recurring industrial engine, and a company that still benefits from several value layers overlapping in the same year.

Working Capital Looks Less Comfortable Than The Cash Balance Suggests

The structure of current liabilities tells the story better than the top-line cash number. Suppliers and service providers rose to NIS 28.6 million from NIS 16.9 million. Other payables rose to NIS 39.9 million from NIS 25.4 million, and inside that line customer advances and deferred income rose to NIS 17.45 million from NIS 6.80 million. On top of that, there was already NIS 9.045 million of dividend payable sitting on the balance sheet at year-end.

At the same time, the current ratio fell to 1.90 from 2.38, working capital declined to NIS 79.97 million from NIS 83.98 million, and equity-to-assets fell to 49.3% from 56.5%. In other words, the company exits 2025 with more cash, but a somewhat less comfortable balance-sheet quality. This is not a survival problem. It is simply a reminder that part of the year’s cash build was also carried by suppliers, advances, and a dividend not yet paid.

Debt Is Mostly Customer Financing, And That Is Both An Edge And A Risk

The company explicitly states that, at the balance-sheet date, it had no loans for ordinary ongoing operations except financing taken in order to provide customer loans for equipment purchases. As of December 31, 2025, total credit from banks and others stood at NIS 18.652 million. In part of these transactions the customer pays a 10% to 30% down payment, and the balance is spread over 3 to 5 years at an average 4.5% interest rate linked to the transaction currency, against matched bank or supplier financing.

That matters because it means Aran is not only a distributor. It also finances customers as part of the machine sale. That is a real competitive capability, but also real balance-sheet usage. As long as the collateral, liens, guarantees, and insurance work as intended, this is a sales enabler. If commercial terms get harder, it can become a layer that weighs on cash flow and flexibility.

Forecasts And Outlook

Before getting into the details, four non-obvious points need to stay on the table:

• First: 2025 already proved defense demand, but it did not yet prove clean defense earnings.
• Second: running below 50% of potential production capacity is upside, but it is also an admission that the industrial engine still lacks enough density.
• Third: growth in equipment and raw materials can continue even with lower margin if the mix stays distribution-heavy.
• Fourth: both 2025 profit and 2025 cash benefited from the Upstream milestone and from working-capital help that may not repeat in the same way.

2026 Is A Proof Year

This is not a reset year. The company enters it with backlog, cash, defense demand already proven by orders, and a recycling leg that is gaining real weight. But it is not a proven breakout year either. For 2026 to look like a real step-up in business quality, three things need to happen together: the defense backlog has to move into profit, margin in equipment and raw materials has to stabilize, and the industrial core has to carry the numbers even without another medical milestone doing the heavy lifting.

What Has To Happen In Defense

At year-end 2025, NIS 33.7 million of the design, development, and manufacturing backlog was already scheduled for 2026, with another NIS 7.6 million for 2027. After the report date, another roughly NIS 7 million was added for 2026, and then another NIS 8.5 million of Ministry of Defense orders came on top. That means the work is already in the pipeline.

It does not yet mean the margin is there. That will be the key test across the next 2 to 4 quarters. If backlog keeps moving mainly through consulting-heavy work or through projects priced too tightly relative to supply-chain pressure, the shop floor may stay busy while the operating result remains thin.

What Has To Happen In Equipment, Raw Materials, And Recycling

In this engine the story is different. The company has already proved it can grow volume. Now it needs to show that the growth is not just a lower-margin distribution story. The start of ExxonMobil PP sales during 2026 can help revenue. The EUR 5.2 million waste-sorting project can help both differentiation and margin. But if most of the momentum remains centered on raw materials and distribution, the market will continue to read this segment first through working capital and margin, and only then through top-line growth.

What Has To Happen Above Upstream

The company estimates that, based on 2025 production levels, the additional manufacturing period at Upstream through September 2026 can generate about NIS 10 million of sales and around NIS 4 million of net profit at the Upstream level, of which roughly NIS 3 million would be attributable to Aran Dgamim. That is a positive possibility, but the framing still matters: even if that estimate is achieved, it does not solve the group’s earnings-quality question by itself. At most, it buys more time for the industrial core to prove itself.

External Bottlenecks Still Matter

The company itself highlights several external frictions that deserve to be taken seriously. In defense, the lack of an approved state budget can delay the move from plans and procurement processes into actual orders. In imports, shekel strength against the dollar compresses revenue and gross margin. And in equipment sales, the 2026 read still depends on normal access to raw materials, timely supply, and customer financing on workable terms.

That is why 2026 will not be judged only by whether Aran grows revenue. It will be judged by whether it can replace profit created through medical monetization and working-capital support with profit created inside the factories, production lines, and repeatable project flow.

Risks

The risks at Aran do not sit in one explosive line item. They sit in the interaction between concentration, earnings quality, working capital, and liquidity.

Profit Still Relies On A Non-Repeatable Layer

The first risk is that the market reads 2025 as cleaner than it really was. The EUR 5 million Upstream milestone created a NIS 16 million pretax gain, and in the startup segment one customer, Bentley, generates 100% of revenue. That is a real layer of value, but it is also concentrated and not the sort of earnings layer that can be assumed to recur in the same shape.

Concentration In Customers, Suppliers, And Key Management

In design and manufacturing, four defense customers account for about 62% of segment revenue. At the group level, one major customer accounted for about NIS 31.1 million, around 11.8% of total revenue in 2025. On the supplier side, the company discloses dependence on Engel in injection equipment and ExxonMobil in raw materials. Above all of that sits explicit material dependence on CEO Ran Seto. This is not a theoretical warning list. It is a real concentration structure.

Customer Financing, FX, And Budget Timing

The customer-financing model is a commercial edge, but also a financial risk. The company extends credit, takes matched financing against it, and relies on liens, guarantees, and insurance. If customers require more financing or if mix moves too heavily toward machine sales, the balance sheet will have to work harder.

At the same time, the group is exposed to FX. A stronger shekel against the dollar erodes revenue and gross margin in imports, even if part of the customer-credit exposure is naturally offset in the same currency. And in defense, budget delays can still postpone order timing even when demand is there.

Low Liquidity Is A Real Constraint

Trading turnover of only NIS 15,250 on the latest trading date and short interest of 0.00% of float do not suggest that the market has fully discovered the name. They suggest the stock barely trades. That is a practical constraint. Even if 2026 turns out well, the path from operating improvement to share-price recognition may be slower and less efficient than usual.

Conclusions

Aran enters 2026 from an interesting, but not yet clean, position. Defense demand is real, recycling gives it a second leg, and the balance sheet is still not under obvious pressure. But the market will struggle to give full credit as long as most of 2025 profit came from Upstream, and as long as design and manufacturing still do not translate backlog into a clear operating margin.

Put more directly, the question is no longer whether the company can win work. The question is whether it can turn this wave of work into industrial earnings quality, without relying again on the same kind of one-off gain and the same kind of working-capital support.

Current thesis: Aran ends 2025 with real industrial demand, but with earnings that still do not lean enough on the operating core.

What changed: the company no longer reads like a development-only story. It has built real defense backlog, a second leg in recycling and waste, and a larger cash balance. But the center of gravity in profit still sits with Upstream rather than with the design and manufacturing core.

Counter-thesis: the strict read may be too early. Backlog is already real, production capacity is still available, the recycling leg is gaining weight, and cash rose meaningfully. If 2026 captures only part of the hidden operating leverage in the current structure, 2025 may later look like a successful transition year.

What could change the market reading in the near to medium term: proof that defense backlog is moving into profit, stabilization of margin in equipment and raw materials, and continued cash generation without another major medical milestone doing the work.

Why this matters: this is the test point between a company that can occasionally monetize value and a company that can generate repeatable industrial value for common shareholders.

What must happen over the next 2 to 4 quarters: design and manufacturing need to show pretax profit far above NIS 0.4 million, defense backlog has to turn into revenue and margin, equipment and raw materials need to hold pace without another major margin hit, and Upstream has to remain an additive layer rather than the crutch behind the whole story.